Chinese scientists prove US Air Force's Mach 16 engine concept ‘feasible'
A state-backed
Chinese research team has achieved a breakthrough in developing a
hypersonic engine powered by ordinary jet fuel, reigniting global debates over the viability of a technology proposed by
US military nearly 70 years ago.
In a peer-reviewed paper published in the Chinese-language Journal of Aerospace Power, a team of
scientists announced a successful ground test of an oblique detonation engine (ODE) chamber burning RP-3 aviation kerosene.
The experiment, simulating
flight conditions at Mach 8 and and an altitude of 30km (18 miles), ignited and sustained stable detonation waves for over two seconds, which proponents said proved the concept's technical feasibility for military use.
Researchers from the China Academy of Launch Vehicle Technology (CALT) – the nation's premier institute for aerospace propulsion – and Northwestern Polytechnical University jointly revealed the results on May 6.
The ODE concept, first proposed by researchers with the University of Michigan under US Air Force-contract research in 1958, promises propulsion without moving parts by coupling shock waves with combustion.
Nasa scientists theorised in 1978 that it could enable sustained hypersonic cruise from Mach 6 to 16 but the concept faced scepticism due to extreme technical hurdles.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
2 hours ago
- South China Morning Post
China boosts research of Southeast Asian populations overlooked in Human Genome Project
For more than two decades, the Human Genome Project (HGP) – a landmark scientific endeavour led by Western nations – mapped humanity's genetic blueprint, yet the rich diversity of Southeast Asia was overlooked. Despite being home to nearly 300 million people, including the world's largest indigenous population, mainland Southeast Asia (MSEA) contributed a mere 1.57 per cent to global genomic databases, with most data derived from diaspora communities rather than local populations. Chinese researchers say they now aim to rectify the omission. Scientists from the Kunming Institute of Zoology, an affiliate of the Chinese Academy of Sciences, have spearheaded a decade-long collaboration with 34 Southeast Asian research teams, culminating in the first comprehensive genomic atlas of the region – the SEA3K data set – which was published in Nature on May 14. 02:43 Nobel Medicine Prize awarded to US duo for 'fundamentally important' discovery of microRNA Nobel Medicine Prize awarded to US duo for 'fundamentally important' discovery of microRNA The study revealed striking insights, including that MSEA populations harbour unique genetic adaptations to tropical challenges as well as distinct Denisovan ancestry linked to Russia's far east. Before China took a role in the research, fewer than 200 indigenous genomes from MSEA existed in global databases, with neighbouring India contributing most via Southeast Asian diaspora samples, according to the paper. Even city state Singapore, a regional sequencing hub, accounted for 92 per cent of the region's limited data, leaving Cambodia, Laos, Myanmar, Thailand and Vietnam virtually invisible in the genomic era. 'For over a decade, we conducted fieldwork in Southeast Asian rainforests, adhering to local ethical protocols, fostering community engagement and documenting indigenous cultural and linguistic contexts,' corresponding author Su Bing said in an interview with China Science Daily on May 19. Researchers collected samples from Southeast Asian populations covering six countries, five prominent language families and 30 ethnic languages. They completed genome sequencing for 3,023 cases, including 40 high-accuracy long-read sequencing data.
South China Morning Post
2 hours ago
- South China Morning Post
Chinese biotech firm Akeso tumbles on US partner Summit's setback for cancer drug
Chinese biotech firm Akeso, whose cancer drug has been hailed as a breakthrough for the nation's pharmaceutical industry, suffered a setback after less favourable clinical data dashed hopes for a quick US regulatory approval. Advertisement Akeso's shares fell 11.6 per cent to HK$73.65 in the morning session on Monday. US partner Summit Therapeutics' Nasdaq-listed shares slumped 30.5 per cent on Friday to US$18.22, the lowest since April 9. Summit said on Friday that the US Food and Drug Administration (FDA) indicated that a 'statistically significant' benefit on overall survival – from start of treatment to death – was required to support marketing approval for the ivonescimab antibody. Ivonescimab targets non-small cell lung cancer patients whose tumours showed a genetic abnormality that drives unusual cell growth. Akeso is based in Zhongshan in China's southern Guangdong province. Photo: Handout Summit said the first global phase-three clinical trial of Akeso's ivonescimab showed that it was effective in restoring patients' immune systems capabilities to attack tumour cells and slowed tumour progression. But ivonescimab had not yet demonstrated a survival benefit for patients in the study.
South China Morning Post
7 hours ago
- South China Morning Post
XPrize founder Peter Diamandis projects hope for AI, biotech amid US-China tech war
Peter Diamandis, the entrepreneur behind the XPrize Foundation, has long championed a future of technological promise, building a career on innovation competitions meant to solve grand challenges. But in a recent conversation in Hong Kong, a subtle shift in tone emerged as he addressed the current complexities of global scientific collaboration, clouded by geopolitical tensions and the looming threat of technological decoupling. Advertisement 'One of the things that is important to realise is that human biology is conserved across 8 billion people, as is math and physics and chemistry,' he said. 'So a breakthrough by a brilliant entrepreneur or scientist in Beijing is fully usable and accessible by a brilliant scientist in Boston. That elevates humanity as a whole.' His cosmopolitan vision of scientific progress stands in contrast to the current political climate, in which the US, under the administration of President Donald Trump, has sought to curb international student visas and made drastic cuts to scientific funding and universities. 'There's a huge amount of concern,' Diamandis said, pointing specifically to the cuts at the National Institutes of Health. 'Unless it gets corrected and changed back, I think that the cuts being made … will have long-term implications to the speed of scientific discoveries.' Diamandis spoke with the Post on May 28 while visiting Hong Kong for the UBS Asian Investment Conference. He is perhaps best known for incentivising breakthroughs through his XPrize competitions, which served as an early catalyst for the private space flight industry that spawned companies such as Elon Musk's SpaceX and Jeff Bezos' Blue Origin. Discussing the more positive aspects of technological progress is clearly where he feels most comfortable. Advertisement 'Our brains are wired for fear and scarcity, and my job through my work is to help people see the world in a different fashion,' he said.
